Next Article in Journal
Are Chlamydia Trachomatis and Neisseria Gonorrhoeae Screenings in Pregnant Women Being Properly Performed? A Single-Center Retrospective Observational Study in Italy
Next Article in Special Issue
Grade C Molar-Incisor Pattern Periodontitis in Young Adults: What Have We Learned So Far?
Previous Article in Journal
Dementia Prevalence and Onchocerca volvulus Infection among Rural Elderly Persons in the Ntui Health District, Cameroon: A Population-Based Study
Previous Article in Special Issue
Dormancy-like Phenotype of Aggregatibacter actinomycetemcomitans: Survival during Famine
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Leukotoxin A Production and Release by JP2 and Non-JP2 Genotype Aggregatibacter actinomycetemcomitans in Relation to Culture Conditions

1
Department of Preventive Dentistry, Periodontology and Implant Biology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
2
Department of Odontology, Umeå University, 90187 Umeå, Sweden
*
Author to whom correspondence should be addressed.
Pathogens 2024, 13(7), 569; https://doi.org/10.3390/pathogens13070569
Submission received: 7 May 2024 / Revised: 19 June 2024 / Accepted: 4 July 2024 / Published: 6 July 2024
(This article belongs to the Special Issue Aggregatibacter actinomycetemcomitans)

Abstract

:
Aggressive forms of periodontitis, especially in young patients, are often associated with an increased proportion of the Gram-negative bacterium Aggregatibacter actinomycetemcomitans of the microbiota of the affected periodontal sites. One of the virulence factors of A. actinomycetemcomitans is a leukotoxin (LtxA) that induces a pro-inflammatory cell death process in leukocytes. A. actinomycetemcomitans exhibits a large genetic diversity and different genotypes vary in LtxA production capacity. The genotype JP2 is a heavy LtxA producer due to a 530-base pair deletion in the promoter for the toxin genes, and this trait has been associated with an increased pathogenic potential. The present study focused on the production and release of LtxA by different A. actinomycetemcomitans genotypes and serotypes under various growth conditions. Four different strains of this bacterium were cultured in two different culture broths, and the amount of LtxA bound to the bacterial surface or released into the broths was determined. The cultures were examined during the logarithmic and the early stationary phases of growth. The JP2 genotype exhibited the highest LtxA production among the strains tested, and production was not affected by the growth phase. The opposite was observed with the other strains. The composition of the culture broth had no effect on the growth pattern of the tested strains. However, the abundant release of LtxA from the bacterial surface into the culture broth was found in the presence of horse serum. Besides confirming the enhanced leucotoxicity of the JP2 genotype, the study provides new data on LtxA production in the logarithmic and stationary phases of growth and the effect of media composition on the release of the toxin from the bacterial membrane.

1. Introduction

The Gram-negative facultative anaerobic bacterial species Aggregatibacter actinomycetemcomitans is associated with periodontitis in young individuals [1,2]. A leukotoxin (LtxA) produced by this bacterium is closely linked to the initiation of degenerative processes involved in the disease [3,4]. LtxA is a large pore-forming protein internalized by the β2 integrin LFA-1 (CD11a/CD18) expressed by human immune cells [5]. The interaction of LtxA with leukocytes activates the release of interleukin (IL)-1β from human macrophages and of proteolytic enzymes from neutrophils [6] and ultimately causes cell death. LtxA-induced macrophage death involves the activation of the NLRP3 inflammasome in a process defined as pyroptosis [7]. The NLRP3 inflammasome plays a central role in many degenerative diseases and is a possible target for future strategies in periodontal therapy [8]. A. actinomycetemcomitans shows a substantial genetic diversity and seven serotypes (a–g) have been described till now [9,10]. A specific variant of serotype b, the JP2 genotype, produces large amounts of LtxA and is characterized by the absence of a 530-base pair (bp) sequence within the ltxCABD promoter region [11].
The JP2 genotype was initially detected in individuals with origins in the Mediterranean part of Africa, following a dissemination route through West Africa, and further to North and South America via the transatlantic slave trade [12]. Today, there are several reports on the carriage of the JP2 genotype by individuals outside the North and West African regions [13]. Young carriers of the JP2 genotype of A. actinomycetemcomitans are at high risk of developing periodontitis [14]. In addition to the JP2 genotype, an additional marker for highly leukotoxic genotypes of A. actinomycetemcomitans has been discovered [15]. This genotype contains an intact cagE gene and includes JP2, as well as a subgroup of non-JP2 isolates with genetic similarities to JP2 [16].
LtxA production substantially varies among different genotypes, being highest in strains of the JP2 genotype [17]. The role of the 530 bp deletion in the promoter region of the leukotoxin operon for the regulation of LtxA expression is not fully understood [18]. The deletion of a specific 100 bp region within the 530 bp promoter deletion region was shown to be a leukotoxin repressor, thus enhancing LtxA production [19]. As a supplement to this finding another recently discovered leukotoxin promoter deletion outside this 100 bp deletion also resulted in enhanced LtxA production in the JP2 genotype, further illustrating the complexity of leukotoxin production [20]. These discrepancies in the role of the promoter deletion for LtxA production indicate a complex regulation with alternative signaling pathways. Environmental factors and growth conditions have also been described as interfering with LtxA production [21,22,23].
LtxA is a 1055 amino acid protein post-translationally activated through acylation before being secreted by a Type I secretion system [24]. The secreted LtxA may either be released into the culture media or stay bound to the bacterial outer membrane [25,26]. The presence of serum proteins induces the release of LtxA from the bacterial outer membrane [27]. The ionic strength of the environment also affects this release [28]. Serum protease inhibitors protect LtxA from proteolytic degradation, which, in turn, promotes increased leukotoxic activity [29].
The aim of the present study was to examine LtxA production by the JP2 and non-JP2 genotypes of A. actinomycetemcomitans in relation to certain culture conditions, such as the culture medium and the phase of growth.

2. Materials and Methods

2.1. Culture Media and Bacterial Strains

Two sterile-filtered culture broths, peptone yeast extract glucose (PYG) [4] and Bacteroides medium (BM) [30] were used. Their composition is shown in Table 1. All chemicals were obtained from Sigma-Aldrich (St. Louis, MA, USA).
The growth of four A. actinomycetemcomitans strains, NCTC 9710, HK 1519 (JP2 genotype), SUNY ab75, and Y4, isolated from human plaque, was initially examined in the two broths (Table 2). A total of 1 mL of an overnight culture was inoculated into 50 mL of fresh broth and incubated at 37 °C in air with 5% CO2. The bacterial growth was followed by measuring the optical density at 600 nm (OD600) of the culture at certain time points. The growth was followed for 24 h.
For the analysis of LtxA production, half of the culture was harvested in the late logarithmic phase of growth after about 8 h of incubation and the rest of the culture after an additional 12 h incubation, i.e., in the stationary phase of growth.

2.2. Extraction of LtxA from Bacterial Cells

Each culture sample was immediately centrifuged at 10,000× g and 4 °C for 30 min, and the bacterial pellet was re-suspended in 50 mM phosphate buffer containing 0.45 M NaCl, pH 7.0, and the density was adjusted to 3 × 1011 cells/mL. The suspension was incubated under gentle rocking at 4 °C for 1 h to release LtxA and other outer membrane proteins from the bacterial cells [28]. At the end of the incubation, the cells were removed by centrifugation (10,000× g at 4 °C for 20 min), and the supernatant was stored at −80 °C until analyzed.

2.3. Precipitation of LtxA Released into the Culture Medium

LtxA and other proteins released from the bacteria into the broth were precipitated by the addition of trichloroacetic acid to the culture supernatant to a final concentration of 5% and incubated overnight at 4 °C. The precipitate was harvested by centrifugation (3000× g at 4 °C for 15 min) and resuspended in 0.1 M NaOH to a final volume that corresponded to protein extraction from 3 × 1011 bacteria/mL, this concentration being comparable with the one in LtxA extracts from the bacterial cells. The solution was stored at −80 °C until analyzed.

2.4. Detection of LtxA in Electrophoresis Gel

The proteins in the precipitates of culture broths and in cell extracts were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE, 8%). Each sample was mixed with an equal volume of buffer (50 µL 50 mM Tris-buffer, pH 7.4, containing 2% SDS, 0.03% bromophenol blue, 20% sucrose, and 5% mercaptothion) and heated at 100 °C for 5 min. The protein bands in the gel were stained with Coomassie brilliant blue R-250 (Bio-Rad Laboratories, Hercules, CA, USA) and the amount of protein in the 116 kDa band that corresponds to leukotoxin was coarsely determined with the Model Gs-700 Imaging Densitometer and the Molecular Analyst™ software version 1.4 (Bio-Rad Laboratories).

2.5. Detection of LtxA by Western Blot Analysis and Amino Acid Sequencing

The proteins in the SDS-PAGE were transferred from the gel to a Polyscreen™ transfer membrane (NEN Life Science Products, Mechelen, Belgium) as previously described [28]. The membrane was incubated in a TBS buffer (20 mM Tris and 500 mM NaCl, pH 7.5) containing rabbit anti-leukotoxin serum (diluted 1:1000) for 1–2 h. As a secondary antibody, goat anti-rabbit HRP (DAKO A/S. Glostrup, Denmark) was used (diluted 1:1000 in TBS-buffer) for 1 h. The immunoreactive bands were visualized on film (Kodak) with ECL development solution according to the manufacturer’s instructions (PIERCE, Rockford, IL, USA).
The N-terminal amino acid sequence analysis of the 116 kDa protein band, transferred from the gel to a Polyscreen™ membrane, was performed with the Procise™ 494 (Applied Biosystems, Foster City, CA, USA) protein sequencing system, using programs and chemicals recommended by the manufacturer [28].

2.6. Isolation of PMN from Peripheral Blood

Human polymorphonuclear leukocytes (PMNs) were prepared from peripheral blood collected in sodium heparin-containing vacuum tubes from two healthy donors (co-authors RC and AJ). After sedimentation in Macrodex (Pharmacia, Uppsala, Sweden), the upper phase was centrifuged (150× g at 4 °C for 12 min) and the cell pellet was resuspended in distilled water for 30 s to lyse remaining red blood cells. Thereafter, NaCl was added to make the solution isotonic, and the cells were washed twice with PBS before being resuspended in RPMI medium with 20% fetal calf serum. The cell concentration in the suspension was determined in a Bürker chamber under 400× magnification and adjusted to 4 × 106 cells/mL. The final preparation contained 90–95% PMN cells.

2.7. Assay of Leukotoxic Activity

The leukotoxicity of the various samples was determined by the activity of lactate dehydrogenase [28] released from injured PMN cells upon exposure to the samples. A volume of 75 µL of PMN suspensions (2 × 106 cells/mL) was mixed with an equal volume of bacterial cell suspensions in RPMI with 20% FCS. Mixtures with a bacterial/PMN ratio of 3, 6, 12, 25, 50, 100, and 200 were prepared and incubated at 37 °C in air with 5% CO2 for 2 h. The leukocytes were pelleted by centrifugation (250× g for 5 min), and the activity of lactate dehydrogenase released in the supernatant was determined [31]. The positive and negative controls were PMN lysed with 0.1% Triton X-100 and PMN only in RPMI, respectively.
A leukotoxicity assay was run in triplicate in a 96-well flat-bottomed microtiter plate. The reaction mixture contained 20 µL sample (supernatant from the centrifuged mixtures) and 180 µL LDH-buffer (0.1 M sodium phosphate buffer pH 7.0, with 2 mM Na-pyruvate and 0.154 mM NADH-Na). The activity of LDH was monitored at room temperature in a spectrophotometer (Multiscan MCC/340, Labsystems Diagnostic Oy, Vantaa, Finland) by continuously measuring the change in absorbance at 340 nm, indicative of NADH oxidation, for 2–5 min. The LDH activity of each sample was recorded as the decrease in absorbance/minute (DA) and the relative leukotoxicity (RL) of each sample was expressed in percent (%) and calculated by the formula:
RL (%) = 100 × (DAsample − DAneg.control)/(DApos.control − DAneg.control)

3. Results

3.1. Bacterial Growth

The estimation of bacterial growth in two different culture media did not show any substantial differences among the four tested bacterial strains (Figure 1). All strains reached the stationary phase of growth after 9–11 h of incubation at 37 °C.
The generation time for each bacterial strain in both culture media was calculated and presented in Table 2.

3.2. Cell Surface-Associated LtxA

The extraction of leukotoxin from bacterial cells showed that strains HK 1519 and Y4 produced high amounts of LtxA during the log phase. The LtxA production by the NCTC 9710 and SUNY ab75 strains was very low or undetectable. During the stationary phase, the HK 1519 strain exhibited more LtxA per bacterial cell than during the log phase, while Y4 showed no change in its content of leukotoxin.
In the log phase, both HK 1519 and Y4 had more leukotoxin associated with the bacterial cells in PYG than in BM. On the other hand, during the stationary phase, strain HK 1519 released more leukotoxin in PYG than in BM, while Y4 had more leukotoxin in BM media compared with PYG (Figure 2 and Table 3). Within the quantitative limitations of the method, the JP2 genotype (strain HK 1519) appeared to continue producing high amounts of LtxA also in the stationary phase of growth, while a more variable LtxA production was observed in the other non-JP2 strains (Table 3). This phenomenon seemed most pronounced in PYG broth.
An abundance of LtxA compared with the other proteins in the cell extracts from the JP2 genotype was observed (Figure 2). The analysis of leukotoxin precipitated from the supernatants of the different bacterial cultures showed very low or no detectable amount of leukotoxin in SDS-PAGE gels.
The immunoblotting of gels with the SDS-PAGE separated extracts showed a high specificity of the polyclonal leukotoxin antiserum for the 116 kDa protein band (Figure 3). The amino acid sequence analyses of this protein band showed a complete sequence homology with A. actinomycetemcomitans LtxA, (accession number P16462, https://www.uniprot.org/uniprotkb/P16462/entry, accessed on 7 January 2015).

3.3. LtxA Released in the Culture Broth

The detection of LtxA released into the growth broth was accomplished by the immunoblotting of the proteins precipitated from the culture supernatants and separated by SDS-PAGE, as described above.
The immunoblot revealed antiserum reactivity with proteins precipitated only from BM culture supernatants (Figure 4). The antibodies bound to the protein band with the molecular weight of leukotoxin and to protein bands at positions of lower or higher molecular weights ranging between 70 and >200 kDa.

3.4. Screening of Leukotoxicity by the Cytolytic Assay

The LtxA-induced lysis of human PMNs showed that the JP2 genotype (strain HK1519) exhibited the highest activity irrespective of the culture condition (Figure 5). Strain Y4 also showed leukotoxic activity; however, it was lower than that of the JP2 genotype.
At a ratio of 200 bacteria/PMN, the RLs of HK1519 cells from the logarithmic and stationary growth phases were 60% and 85%, respectively. The corresponding RLs of strain Y4 were lower, ranging from about 20 to 30% (Figure 5).
In all experiments, the leukotoxicity of strains NCTC 9710 and Suny ab75 was somewhat lower compared to the one of strain Y4, and it reached detectable levels under the conditions displayed in Figure 6.

4. Discussion

It is evident from the present findings that the growth conditions may affect the leukotoxicity of A. actinomycetemcomitans, which may partly explain the discrepancies in leukotoxin production and leukotoxicity observed for the same strains by various researchers. Both the composition of the culture medium and the phase of growth at which the bacteria were harvested influenced the relative leukotoxicity; however, strain-dependent patterns were found. Although the leukotoxicity of the non-JP2 genotype strains showed a tendency to be slightly increased in cultures from BM broth, the highest leukotoxic activity is to be expected with all strains when grown in the absence of blood or serum proteins, such as in PYG broth, due to the minimal loss of the toxin from the bacterial surface into the culture medium. Except for the JP2 genotype, which continued its high LtxA production during the stationary phase of growth, the other strains exhibited higher or equally high leukotoxic activity during the logarithmic phase than during the stationary phase of growth. It is worth noting that in the studies mentioned above, A. actinomycetemcomitans was cultured on agar media supplemented with blood or serum, usually for 48 h, before assaying the leukotoxicity. These conditions probably had a considerable impact on the outcome of these studies.
The culture broths studied have a chemically non-defined composition and are widely used for the cultivation of oral bacteria. The two broths supported the growth of all strains tested, and no significant difference was found in either the generation time, the duration of the lag phase, or the final cell density when the cultures reached the stationary phase of growth. Thus, the variation in leukotoxicity cannot be attributed to differences in the growth pattern.
The main difference between PYG and BM broth is the presence of hemin, vitamin K, and horse serum in the latter. Judging from the equally good growth of all strains in both media, it may be suggested that these supplements do not cover the nutritional demands of A. actinomycetemcomitans, as also shown elsewhere [32]. Serum was thought to support growth and was used in selective media to secure good growth upon primary cultivation; however, the opposite effect was observed [33]. Supplementing BM with these compounds was originally suggested to support the growth of fastidious anaerobes such as Prevotella and Porphyromonas species, formerly classified as Bacteroides species [30,34,35].
Despite the similar growth in the two broths, a consistent difference in the release of LtxA from the bacterial cells appears to occur with all strains, with the release being more extensive in BM cultures. The release of membrane-bound active LtxA, both as free molecules and incorporated in outer membrane vesicles, was previously shown to occur upon a 1 h incubation of the bacteria with human serum or serum albumin at 4 °C, with the release being concentration-dependent [27]. Possibly, the horse serum in BM has a similar effect on the release of the toxin.
In the previous study [27], the leukotoxic activity of the JP2 genotype was also examined with cultures in PYG supplemented with various concentrations of human serum. Intact LtxA and other protein bands of smaller molecular weight that reacted with LtxA-antiserum were detected both in the samples of culture supernatants and the cell extracts. However, the preparations lacked leukotoxic activity even from cultures with low serum concentrations (5%), which could possibly depend on the degradation and inactivation of LtxA by the components of the human serum. This was not observed in this study, which may indicate important differences between the inactivated horse serum used in BM and the human serum previously studied.
The Y4 strain seems to produce more LtxA, either released in the medium or kept bound to the bacterial cells, when grown in BM than in PYG. As mentioned, a strain-dependent pattern appears to exist in LtxA production, with the pattern being influenced by the medium composition. Possibly, these strains may respond to small molecules and nutritional cues of their environment with an altered virulence expression, as also observed with other periodontopathogens [36].
In accordance with previous observations, the JP2 genotype (strain HK1519) of A. actinomycetemcomitans exhibited a much higher LtxA production than the non-JP2 genotypes [17]. Moreover, the present results indicate that the enhanced LtxA production by the JP2 genotype is more pronounced during the stationary phase of growth. This strain continued to accumulate LtxA bound to the outer membrane, while the non-JP2 genotype (strain Y4) already reached maximal LtxA content in the late logarithmic growth phase. This is opposite to the large previously reported reduction in LtxA expression in the JP2 genotype when approaching the stationary phase of growth [37]. Differences in the culture conditions may be responsible for the discrepant results, as already mentioned above.
Some authors suggested an enhanced pathogenic potential of A. actinomycetemcomitans strains belonging to serotype b due to their increased LtxA production [4,38]. LtxA induces a substantial pro-inflammatory response in macrophages by targeting the NLRP3 inflammasome [7,39]. The genotyping of serotype b isolates revealed a subgroup with high virulence [40]. More recently, a genetic marker, the cagE gene, was identified for this subgroup [15], which includes the JP2 genotype and about one-third of the non-JP2 serotype b isolates with shared properties of high LtxA production and pathogenicity [16]. The serotype b strain Y4 lacks the cagE gene [16]. This genetic difference between the two serotype b strains HK1519 and Y4 agrees with the large difference in their LtxA production as presently found. It remains to be discovered whether the cagE gene has a role in the enhanced LtxA production and virulence associated with this genotype [15,16].
Extrapolating these in vitro findings to the clinical situation, it seems plausible to expect that the nutritional environment of the inflamed periodontal pocket favors the production and release of LtxA by A. actinomycetemcomitans. Especially, strains characterized as heavy LtxA producers, such as those of the JP2 genotype, might stably express this virulence factor at maximum capacity, irrespective of their growth phase. The high pathogenic potential ascribed to the JP2 genotype [41,42] and to other strains of the cagE subgroup is probably potentiated by the enhanced release of the toxin from the bacterial surface, due to the presence of serum compounds. Depending on the proteolytic activity of the environment, the free LtxA may be degraded and lose its toxicity [28,29] or remain intact. The higher the production and release of LtxA, the higher the amount of intact toxin molecules that may diffuse into the neighboring soft tissue and trigger inflammatory reactions or kill defense cells [6,43]. The present study supports this hypothesis of the pathogenic potential of specific A. actinomycetemcomitans strains and the possible mechanisms.

Author Contributions

Conceptualization, A.J., S.K. and R.C.; methodology, A.J., Z.K.P. and R.C.; software, A.J.; validation, A.J., S.K. and R.C.; formal analysis, A.J., R.C. and Z.K.P.; investigation, R.C. and A.J.; resources, A.J., S.K. and R.C.; data curation, A.J., S.K. and Z.K.P.; writing—original draft preparation, A.J.; writing—review and editing, A.J., S.K., Z.K.P. and R.C.; funding acquisition, A.J. and S.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by TUA grants from the County Council of Västerbotten, Sweden (A.J.; 7003193).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are available from the corresponding author, Department of Odontology, Umeå University.

Acknowledgments

A. actinomycetemcomitans strain HK 1519 (serotype b, JP2 genotype) was kindly provided by M. Kilian, Aarhus, Denmark.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Fine, D.H.; Patil, A.G.; Velusamy, S.K. Aggregatibacter actinomycetemcomitans (Aa) Under the Radar: Myths and Misunderstandings of Aa and Its Role in Aggressive Periodontitis. Front. Immunol. 2019, 10, 728. [Google Scholar] [CrossRef] [PubMed]
  2. Hbibi, A.; Bouziane, A.; Lyoussi, B.; Zouhdi, M.; Benazza, D. Aggregatibacter actinomycetemcomitans: From Basic to Advanced Research. In Periodontitis: Advances in Experimental Research; Springer International Publishing: Cham, Switzerland, 2022; Volume 1373, pp. 45–67. [Google Scholar]
  3. Kelk, P.; Claesson, R.; Chen, C.; Sjöstedt, A.; Johansson, A. IL-1beta secretion induced by Aggregatibacter (Actinobacillus) actinomycetemcomitans is mainly caused by the leukotoxin. Int. J. Med. Microbiol. 2008, 298, 529–541. [Google Scholar] [CrossRef] [PubMed]
  4. Åberg, C.H.; Haubek, D.; Kwamin, F.; Johansson, A.; Claesson, R. Leukotoxic activity of Aggregatibacter actinomycetemcomitans and periodontal attachment loss. PLoS ONE 2014, 9, e104095. [Google Scholar] [CrossRef]
  5. Lally, E.T.; Kieba, I.R.; Sato, A.; Green, C.L.; Rosenbloom, J.; Korostoff, J.; Wang, J.F.; Shenker, B.J.; Ortlepp, S.; Robinson, M.K.; et al. RTX toxins recognize a beta2 integrin on the surface of human target cells. J. Biol. Chem. 1997, 272, 30463–30469. [Google Scholar] [CrossRef]
  6. Johansson, A. Aggregatibacter actinomycetemcomitans leukotoxin: A powerful tool with capacity to cause imbalance in the host inflammatory response. Toxins 2011, 3, 242–259. [Google Scholar] [CrossRef] [PubMed]
  7. Kelk, P.; Moghbel, N.S.; Hirschfeld, J.; Johansson, A. Aggregatibacter actinomycetemcomitans Leukotoxin Activates the NLRP3 Inflammasome and Cell-to-Cell Communication. Pathogens 2022, 11, 159. [Google Scholar] [CrossRef] [PubMed]
  8. Zhao, Y.; Quan, Y.; Lei, T.; Fan, L.; Ge, X.; Hu, S. The Role of Inflammasome NLPR3 in the Development and Therapy of Periodontitis. Int. J. Med. Sci. 2022, 19, 1603–1614. [Google Scholar] [CrossRef] [PubMed]
  9. Kaplan, J.B.; Perry, M.B.; MacLean, L.L.; Furgang, D.; Wilson, M.E.; Fine, D.H. Structural and genetic analyses of O polysaccharide from Actinobacillus actinomycetemcomitans serotype f. Infect. Immun. 2001, 69, 5375–5384. [Google Scholar] [CrossRef] [PubMed]
  10. Kittichotirat, W.; Bumgarner, R.; Chen, C. Evolutionary Divergence of Aggregatibacter actinomycetemcomitans. J. Dent. Res. 2016, 95, 94–101. [Google Scholar] [CrossRef]
  11. Brogan, J.M.; Lally, E.T.; Poulsen, K.; Kilian, M.; Demuth, D.R. Regulation of Actinobacillus actinomycetemcomitans leukotoxin expression: Analysis of the promoter regions of leukotoxic and minimally leukotoxic strains. Infect. Immun. 1994, 62, 501–508. [Google Scholar] [CrossRef]
  12. Haubek, D.; Poulsen, K.; Kilian, M. Microevolution and Patterns of Dissemination of the JP2 Clone of Aggregatibacter (Actinobacillus) actinomycetemcomitans. Infect. Immun. 2007, 75, 3080–3088. [Google Scholar] [CrossRef] [PubMed]
  13. Khzam, N.; Miranda, L.A.; Kujan, O.; Shearston, K.; Haubek, D. Prevalence of the JP2 genotype of Aggregatibacter actinomycetemcomitans in the world population: A systematic review. Clin. Oral Investig. 2022, 26, 2317–2334. [Google Scholar] [CrossRef] [PubMed]
  14. Mehta, J.; Eaton, C.; AlAmri, M.; Lin, G.; Nibali, L. The association between Aggregatibacter actinomycetemcomitans JP2 clone and periodontitis: A systematic review and meta-analysis. J. Periodontal Res. 2023, 58, 465–482. [Google Scholar] [CrossRef]
  15. Johansson, A.; Claesson, R.; Åberg, C.H.; Haubek, D.; Oscarsson, J. The cagE gene sequence as a diagnostic marker to identify JP2 and non-JP2 highly leukotoxic Aggregatibacter actinomycetemcomitans serotype b strains. J. Periodontal Res. 2017, 52, 903–912. [Google Scholar] [CrossRef] [PubMed]
  16. Johansson, A.; Claesson, R.; Åberg, C.H.; Haubek, D.; Lindholm, M.; Jasim, S.; Oscarsson, J. Genetic Profiling of Aggregatibacter actinomycetemcomitans Serotype B Isolated from Periodontitis Patients Living in Sweden. Pathogens 2019, 8, 153. [Google Scholar] [CrossRef] [PubMed]
  17. Jensen, A.B.; Lund, M.; Nørskov-Lauritsen, N.; Johansson, A.; Claesson, R.; Reinholdt, J.; Haubek, D. Differential Cell Lysis Among Periodontal Strains of JP2 and Non-JP2 Genotype of Aggregatibacter actinomycetemcomitans Serotype B Is Not Reflected in Dissimilar Expression and Production of Leukotoxin. Pathogens 2019, 8, 211. [Google Scholar] [CrossRef] [PubMed]
  18. Hritz, M.; Fisher, E.; Demuth, D.R. Differential regulation of the leukotoxin operon in highly leukotoxic and minimally leukotoxic strains of Actinobacillus actinomycetemcomitans. Infect. Immun. 1996, 64, 2724–2729. [Google Scholar] [CrossRef]
  19. Sampathkumar, V.; Velusamy, S.K.; Godboley, D.; Fine, D.H. Increased leukotoxin production: Characterization of 100 base pairs within the 530 base pair leukotoxin promoter region of Aggregatibacter actinomycetemcomitans. Sci. Rep. 2017, 7, 1887. [Google Scholar] [CrossRef]
  20. Claesson, R.; Chiang, H.M.; Lindholm, M.; Höglund Åberg, C.; Haubek, D.; Johansson, A.; Oscarsson, J. Characterization of Aggregatibacter actinomycetemcomitans Serotype b Strains with Five Different, Including Two Novel, Leukotoxin Promoter Structures. Vaccines 2020, 8, 398. [Google Scholar] [CrossRef]
  21. Kolodrubetz, D.; Spitznagel, J.; Wang, B.; Phillips, L.H.; Jacobs, C.; Kraig, E. cis Elements and trans factors are both important in strain-specific regulation of the leukotoxin gene in Actinobacillus actinomycetemcomitans. Infect. Immun. 1996, 64, 3451–3460. [Google Scholar] [CrossRef]
  22. Childress, C.; Feuerbacher, L.A.; Phillips, L.; Burgum, A.; Kolodrubetz, D. Mlc is a transcriptional activator with a key role in integrating cyclic AMP receptor protein and integration host factor regulation of leukotoxin RNA synthesis in Aggregatibacter actinomycetemcomitans. J. Bacteriol. 2013, 195, 2284–2297. [Google Scholar] [CrossRef]
  23. Shakya, S.; Danshiitsoodol, N.; Noda, M.; Inoue, Y.; Sugiyama, M. 3-Phenyllactic acid generated in medicinal plant extracts fermented with plant-derived lactic acid bacteria inhibits the biofilm synthesis of Aggregatibacter actinomycetemcomitans. Front. Microbiol. 2022, 13, 991144. [Google Scholar] [CrossRef] [PubMed]
  24. Fong, K.; Tang, H.; Brown, A.; Kieba, I.; Speicher, D.; Boesze-Battaglia, K.; Lally, E. Aggregatibacter actinomycetemcomitans leukotoxin is post-translationally modified by addition of either saturated or hydroxylated fatty acyl chains. Mol. Oral Microbiol. 2011, 26, 262–276. [Google Scholar] [CrossRef] [PubMed]
  25. Balashova, N.V.; Diaz, R.; Balashov, S.V.; Crosby, J.A.; Kachlany, S.C. Regulation of Aggregatibacter (Actinobacillus) actinomycetemcomitans leukotoxin secretion by iron. J. Bacteriol. 2006, 188, 8658–8661. [Google Scholar] [CrossRef] [PubMed]
  26. Tang, G.; Kawai, T.; Komatsuzawa, H.; Mintz, K.P. Lipopolysaccharides mediate leukotoxin secretion in Aggregatibacter actinomycetem-comitans. Mol. Oral. Microbiol. 2012, 27, 70–82. [Google Scholar] [CrossRef]
  27. Johansson, A.; Claesson, R.; Hänström, L.; Kalfas, S. Serum-mediated release of leukotoxin from the cell surface of the periodontal pathogen Actinobacillus actinomycetemcomitans. Eur. J. Oral Sci. 2003, 111, 209–215. [Google Scholar] [CrossRef] [PubMed]
  28. Johansson, A.; Hänström, L.; Kalfas, S. Inhibition of Actinobacillus actinomycetemcomitans leukotoxicity by bacteria from the subgingival flora. Oral Microbiol. Immunol. 2000, 15, 218–225. [Google Scholar] [CrossRef] [PubMed]
  29. Johansson, A.; Claesson, R.; Belibasakis, G.; Makoveichuk, E.; Hänström, L.; Olivecrona, G.; Sandström, G.; Kalfas, S. Protease inhibitors, the responsible components for the serum-dependent enhancement of Actinobacillus actinomycetemcomitans leukotoxicity. Eur. J. Oral. Sci. 2001, 109, 335–341. [Google Scholar] [CrossRef]
  30. Shah, H.N.; Bowden, G.H.; Hardie, J.M.; Williams, R.A.D. Comparison of the biochemical properties of Bacteroides melaninogenicus from human dental plaque and other sites. J. Appl. Bacteriol. 1976, 41, 473–492. [Google Scholar] [CrossRef]
  31. Johansson, A.; Kalfas, S. Characterization of the proteinase-dependent cytotoxicity of Porphyromonas gingivalis. Eur. J. Oral Sci. 1998, 106, 863–871. [Google Scholar] [CrossRef]
  32. Nørskov-Lauritsen, N.; Kilian, M. Reclassification of Actinobacillus actinomycetemcomitans, Haemophilus aphrophilus, Haemophilus paraphrophilus and Haemophilus segnis as Aggregatibacter actinomycetemcomitans gen. nov., comb. nov., Aggregatibacter aphrophilus comb. nov. and Aggregatibacter segnis comb. nov., and emended description of Aggregatibacter aphrophilus to include V factor-dependent and V factor-independent isolates. Int. J. Syst. Evol. Microbiol. 2006, 56 Pt 9, 2135–2146. [Google Scholar] [PubMed]
  33. Tsuzukibashi, O.; Takada, K.; Saito, M.; Kimura, C.; Yoshikawa, T.; Makimura, M.; Hirasawa, M. A novel selective medium for isolation of Aggregatibacter (Actinobacillus) actinomycetemcomitans. J. Periodontal Res. 2008, 43, 544–548. [Google Scholar] [CrossRef] [PubMed]
  34. Hunt, D.E.; Jones, J.V.; Dowell, V.R. Selective medium for the isolation of Bacteroides gingivalis. J. Clin. Microbiol. 1986, 23, 441–445. [Google Scholar] [CrossRef]
  35. Gibbons, R.J.; Macdonald, J.B. Hemin and vitamin K compounds as required factors for the cultivation of certain strains of Bacteroides melaninogenicus. J. Bacteriol. 1960, 80, 164–170. [Google Scholar] [CrossRef] [PubMed]
  36. Lamont, R.J.; Kuboniwa, M. The polymicrobial pathogenicity of Porphyromonas gingivalis. Front. Oral Health 2024, 5, 1404917. [Google Scholar] [CrossRef] [PubMed]
  37. Spitznagel, J., Jr.; Kraig, E.; Kolodrubetz, D. Regulation of leukotoxin in leukotoxic and nonleukotoxic strains of Actinobacillus actinomycetemcomitans. Infect. Immun. 1991, 59, 1394–1401. [Google Scholar] [CrossRef]
  38. Yang, H.W.; Asikainen, S.; Doğan, B.; Suda, R.; Lai, C.H. Relationship of Actinobacillus actinomycetemcomitans serotype b to aggressive periodontitis: Frequency in pure cultured isolates. J. Periodontol. 2004, 75, 592–599. [Google Scholar] [CrossRef]
  39. Kelk, P.; Johansson, A.; Claesson, R.; Hanstrom, L.; Kalfas, S. Caspase 1 involvement in human monocyte lysis induced by Actinobacillus actino-mycetemcomitans leukotoxin. Infect. Immun. 2003, 71, 4448–4455. [Google Scholar] [CrossRef] [PubMed]
  40. Asikainen, S.; Chen, C.; Slots, J. Actinobacillus actinomycetemcomitans genotypes in relation to serotypes and periodontal status. Oral Microbiol. Immunol. 1995, 10, 65–68. [Google Scholar] [CrossRef] [PubMed]
  41. Haubek, D.; Ennibi, O.-K.; Poulsen, K.; Væth, M.; Poulsen, S.; Kilian, M. Risk of aggressive periodontitis in adolescent carriers of the JP2 clone of Aggregatibacter (Actinobacillus) actinomycetemcomitans in Morocco: A prospective longitudinal cohort study. Lancet 2008, 371, 237–242. [Google Scholar] [CrossRef]
  42. Krueger, E.; Brown, A.C. Aggregatibacter actinomycetemcomitans leukotoxin: From mechanism to targeted anti-toxin therapeutics. Mol. Oral Microbiol. 2020, 35, 85–105. [Google Scholar] [CrossRef] [PubMed]
  43. Johansson, A.; Kalfas, S. Virulence mechanisms of leukotoxin from Aggregatibacter actinomycetem-comitans. In Oral Health Care, Prosthodontics, Periodontology, Biology, Research and Systemic Conditions; IntechOpen: London, UK, 2012; Volume 2, pp. 165–192. [Google Scholar]
Figure 1. Growth curves in PYG and BM broths of the four bacterial strains. The growth was determined by the change in the optical density of the culture at 600 nm (OD600).
Figure 1. Growth curves in PYG and BM broths of the four bacterial strains. The growth was determined by the change in the optical density of the culture at 600 nm (OD600).
Pathogens 13 00569 g001
Figure 2. Cell surface-associated LtxA extracted from A. actinomycetemcomitans strains cultured in PYG or BM broth. The cells were harvested during the logarithmic (A) or stationary (B) phases of growth. The leukotoxin appears as a protein band at the 116 kDa position (arrow) in SDS-PAGE (8%). Data from representative experiments are shown.
Figure 2. Cell surface-associated LtxA extracted from A. actinomycetemcomitans strains cultured in PYG or BM broth. The cells were harvested during the logarithmic (A) or stationary (B) phases of growth. The leukotoxin appears as a protein band at the 116 kDa position (arrow) in SDS-PAGE (8%). Data from representative experiments are shown.
Pathogens 13 00569 g002
Figure 3. Western blot analysis (with polyclonal rabbit LtxA antiserum) of cell surface-associated LtxA extracted from A. actinomycetemcomitans strains cultured in PYG or BM broth. The cells were harvested during the logarithmic (A) or stationary (B) phases of growth. Data from representative experiments are shown. The leukotoxin appears at the 116 kDa position (arrow).
Figure 3. Western blot analysis (with polyclonal rabbit LtxA antiserum) of cell surface-associated LtxA extracted from A. actinomycetemcomitans strains cultured in PYG or BM broth. The cells were harvested during the logarithmic (A) or stationary (B) phases of growth. Data from representative experiments are shown. The leukotoxin appears at the 116 kDa position (arrow).
Pathogens 13 00569 g003
Figure 4. Western blots of proteins precipitated from culture supernatants of various A. actinomycetemcomitans strains and separated by SDS-PAGE before being exposed to polyclonal rabbit LtxA antiserum. The supernatants were collected during the logarithmic or stationary phases of growth in PYG (A) or BM (B) broth. Data from representative experiments are shown.
Figure 4. Western blots of proteins precipitated from culture supernatants of various A. actinomycetemcomitans strains and separated by SDS-PAGE before being exposed to polyclonal rabbit LtxA antiserum. The supernatants were collected during the logarithmic or stationary phases of growth in PYG (A) or BM (B) broth. Data from representative experiments are shown.
Pathogens 13 00569 g004
Figure 5. Relative leukotoxicity of A. actinomycetemcomitans HK1519 and Y4 grown in PYG or BM broth and harvested during the logarithmic (grey bars) or stationary (black bars) phases of growth. The leukotoxic activity was examined at various ratios of bacteria/PMN.
Figure 5. Relative leukotoxicity of A. actinomycetemcomitans HK1519 and Y4 grown in PYG or BM broth and harvested during the logarithmic (grey bars) or stationary (black bars) phases of growth. The leukotoxic activity was examined at various ratios of bacteria/PMN.
Pathogens 13 00569 g005
Figure 6. Leukotoxicity of A. actinomycetemcomitans strains NCTC 9710 and SUNY ab75 under different growth conditions. Mean ± SD of three replicates.
Figure 6. Leukotoxicity of A. actinomycetemcomitans strains NCTC 9710 and SUNY ab75 under different growth conditions. Mean ± SD of three replicates.
Pathogens 13 00569 g006
Table 1. Composition of the two culture broths.
Table 1. Composition of the two culture broths.
PYG MediumBM Medium
Bacto peptone 0.5%Trypticase (BBL) 1%
Trypticase peptone 0.5%Proteose peptone (Oxoid) 1%
Glucose 1%Glucose 0.5%
Yeast extract 1%,Yeast extract 0.5%
NaCl 1.36 mM NaCl 1.13 mM
MgSO4 0.03 mMSterile horse serum 2%
K2HPO4 0.22 mMHemin 5 mg/L
KH2PO4 0.29 mMVitamin K 10 mg/L
CaCl2 0.05 mM
NaHCO3 4.7 mM
Table 2. Generation time in minutes of various strains of A. actinomycetemcomitans in two different culture media. Mean ± standard deviation of 3 experiments with each strain.
Table 2. Generation time in minutes of various strains of A. actinomycetemcomitans in two different culture media. Mean ± standard deviation of 3 experiments with each strain.
A. actinomycetemcomitans StrainsPYG BrothBM Broth
NCTC 9710 (serotype c)92 ± 996 ± 6
HK 1519 (serotype b, JP2 genotype)108 ± 696 ± 27
SUNY ab75 (serotype a)116 ± 1294 ± 24
Y4 (serotype b, non-JP2 genotype)92 ± 992 ± 18
Table 3. Leukotoxin content of extracts from bacteria cultured in two different media and harvested during the logarithmic or stationary phases of growth. The amount of leukotoxin was determined by densitometric analysis (OD × mm2) of the LtxA band in the SDS-PAGE of the extracts. Data from two experiments (Exp. 1 and Exp. 2) with each strain are presented.
Table 3. Leukotoxin content of extracts from bacteria cultured in two different media and harvested during the logarithmic or stationary phases of growth. The amount of leukotoxin was determined by densitometric analysis (OD × mm2) of the LtxA band in the SDS-PAGE of the extracts. Data from two experiments (Exp. 1 and Exp. 2) with each strain are presented.
StrainPYG BrothBM Broth
LogarithmicStationaryLogarithmicStationary
Exp. 1Exp. 2Exp. 1Exp. 2Exp. 1Exp. 2Exp. 1Exp. 2
NCTC 97100.140.680.730.67−0.020.941.330.81
HK15192.854.7219.78.752.541.627.657.10
SUNY ab750.250.170.710.680.740.640.911.51
Y43.811.521.241.611.661.873.082.79
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kalfas, S.; Pour, Z.K.; Claesson, R.; Johansson, A. Leukotoxin A Production and Release by JP2 and Non-JP2 Genotype Aggregatibacter actinomycetemcomitans in Relation to Culture Conditions. Pathogens 2024, 13, 569. https://doi.org/10.3390/pathogens13070569

AMA Style

Kalfas S, Pour ZK, Claesson R, Johansson A. Leukotoxin A Production and Release by JP2 and Non-JP2 Genotype Aggregatibacter actinomycetemcomitans in Relation to Culture Conditions. Pathogens. 2024; 13(7):569. https://doi.org/10.3390/pathogens13070569

Chicago/Turabian Style

Kalfas, Sotirios, Zahra Khayyat Pour, Rolf Claesson, and Anders Johansson. 2024. "Leukotoxin A Production and Release by JP2 and Non-JP2 Genotype Aggregatibacter actinomycetemcomitans in Relation to Culture Conditions" Pathogens 13, no. 7: 569. https://doi.org/10.3390/pathogens13070569

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop